Autolus Therapeutics Plc ADR (AUTL) Stock Price, Quote & News

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL;...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3829 6230

Website: www.autolus.com

Address:

The Mediaworks, 191 Wood Lane White City, London, United Kingdom

Biotechs5454 Apr. 14 at 3:30 PM

$AUTL Relative to what we usually see, seems like some bigger bids (and asks) on lvl II than the norm.

2 · Reply

smar312 Apr. 14 at 2:43 PM

$AUTL https://seekingalpha.com/news/4574669-asgard-therapeutics-names-wolfram-brugger-as-chief-medical-officer-to-lead-clinical-transition#:~:text=Asgard%20Therapeutics%20names%20Wolfram%20Brugger%20as%20chief%20medical%20officer%20to%20lead%20clinical%20transition

2 · Reply

Michael_garic Apr. 14 at 2:01 PM

$AUTL My opinion is that ALLO is a case study on how clinical biotechs work. They announce in their last earnings call they have enough cash runway to last till 2028. They have a webcast yesterday announcing positive test results that beat their own stated low bar milestones. The stock takes off from $2.60 to almost $5.00 after the announcement, then after hours they announce a stock offering. You would think that they would have been honest in the first press release with trial results and stock offering. Making two separate announcements allowed the stock to rise and some folks to make money, then come back with a surprise impacting some new investors that paid the higher price. I'm not sure I would trust their management going forward? I hope AUTL doesn't try this nonsense.

2 · Reply

Michael_garic Apr. 14 at 1:03 PM

$AUTL Still remember this quote

0 · Reply

NANANANANANANAN Apr. 14 at 12:47 PM

$AUTL Dilution incoming

0 · Reply

Michael_garic Apr. 14 at 12:03 PM

$AUTL I saw a question about the AUTL 150M shelf offering or S-3. This does not mean that AUTL is immediately selling stock but gives them the right to sell. The filing specifically lists clinical development, manufacturing, and the commercialization of AUCATZYL as the intended uses. Autolus is also fulfilling a legal obligation to register these shares so that if Blackstone or BioNTech decides to sell in the future, the shares are already "cleared" for the public market. AUTL would get zero dollars for this type of sale. With the commercial launch underway and expansion into autoimmune trials (Lupus/MS), they want the flexibility to "tap the market" if their stock price spikes or if they need a sudden cash infusion to scale manufacturing. Example: ALLO, in the March earnings call stated they had enough cash runway to fund operations until Q1 2028 but decided yesterday, when their stock rose, to have a 150M public offering. AUTL could legally do the same thing.

2 · Reply

Michael_garic Apr. 14 at 6:36 AM

$AUTL Wainwright issued more realistic EPS numbers and reiterated buy rating for AUTL https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-outlook-for-autl-earnings-2026-04-13/

1 · Reply

billyl Apr. 14 at 2:49 AM

$AUTL Bull Case Commercial inflection underway • 1st approved product AUCATZYL (obe-cel) now generating revenue • ~$75M in 2025 sales; guided to $120–135M in 2026 → strong early ramp • Launch expanding to 60+ treatment centers → improving adoption Strong clinical profile (differentiated CAR-T) • High efficacy in ALL: • ~95% overall response rate (pediatric data) • Favorable safety vs older CAR-T (lower toxicity, better persistence) 👉 key: safety/tolerability is a major differentiator in CAR-T Pipeline expansion beyond oncology (big upside lever) • Moving into autoimmune diseases: • Lupus (LUMINA) • Progressive MS (BOBCAT trial; data expected late 2026) • Pediatric ALL pivotal study • AL amyloidosis (Phase 1) 👉 If CAR-T works in autoimmune → massive TAM expansion Investing in automated manufacturing (Cellares platform) to scale production • Lower COGS • Higher margins • Greater capacity • estimated Rev growth ~39% annually • Earnings growth ~25%

0 · Reply

gandolf63 Apr. 13 at 11:53 PM

$AUTL He said Autolus estimates there are about 4,000 to 5,000 adult frontline ALL patients annually in the U.S., and he expects “about half” may fall into categories not well served by current standard of care. He said frontline efforts are currently being evaluated in investigator-sponsored trials, including work at MD Anderson, a study involving Memorial, Stanford, and City of Hope, and a third study being initiated in Europe https://www.marketbeat.com/instant-alerts/autolus-therapeutics-eyes-car-t-edge-with-aucatzyl-safety-expands-centers-sees-margin-turnaround-2026-04-13/#google_vignette

0 · Reply

Michael_garic Apr. 13 at 8:50 PM

$AUTL ALLO interesting day. First the positive announcement, then after hours a 175M stock dilution. This indicates that they need additional funding to continue trials. The joys of biotech.

0 · Reply

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Mar 27, 2026, 7:00 AM EDT - 18 days ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

Mar 16, 2026, 4:10 PM EDT - 4 weeks ago

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

Feb 4, 2026, 8:57 AM EST - 2 months ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 7:00 AM EST - 3 months ago

Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026

Jan 6, 2026, 9:00 AM EST - 3 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform

Jan 6, 2026, 9:00 AM EST - 3 months ago

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

$Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025$

Dec 8, 2025, 4:05 PM EST - 4 months ago

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 8, 2025, 8:35 AM EST - 4 months ago

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Dec 1, 2025, 7:00 AM EST - 4 months ago

Autolus Therapeutics Appoints Ryan Richardson to Board of Directors

Nov 25, 2025, 12:37 PM EST - 4 months ago

Why Is Autolus Therapeutics Stock Trading Higher On Tuesday?

$NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹$

Nov 25, 2025, 4:00 AM EST - 5 months ago

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Nov 13, 2025, 4:05 PM EST - 5 months ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:00 AM EST - 5 months ago

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 3, 2025, 9:05 AM EST - 5 months ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Oct 30, 2025, 7:00 AM EDT - 5 months ago

Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Oct 27, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Oct 20, 2025, 7:00 AM EDT - 6 months ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

Sep 16, 2025, 8:05 AM EDT - 7 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

Aug 12, 2025, 7:00 AM EDT - 8 months ago

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jul 24, 2025, 7:30 AM EDT - 9 months ago

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

$Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

Jul 21, 2025, 7:00 AM EDT - 9 months ago

Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Jun 12, 2025, 2:00 AM EDT - 10 months ago

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

May 23, 2025, 8:30 AM EDT - 11 months ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

May 14, 2025, 9:30 AM EDT - 11 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

May 8, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

Apr 25, 2025, 12:06 PM EDT - 1 year ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Apr 22, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 6, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Jan 17, 2025, 7:00 AM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Dec 9, 2024, 7:30 PM EST - 1 year ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

Nov 8, 2024, 4:23 PM EST - 1 year ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Oct 28, 2024, 5:00 PM EDT - 1 year ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Jul 26, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

May 31, 2024, 8:00 AM EDT - 2 years ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

May 17, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Apr 24, 2024, 10:00 AM EDT - 2 years ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Announces Changes to its Board of Directors

Mar 14, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 7:00 AM EDT - 2 years ago

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Feb 29, 2024, 7:00 AM EST - 2 years ago

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 8, 2024, 7:00 AM EST - 2 years ago

Autolus Announces Pricing of Underwritten Offering

Feb 8, 2024, 5:45 AM EST - 2 years ago

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Jan 23, 2024, 7:00 AM EST - 2 years ago

Autolus Therapeutics announces publication in ACS Chemical Biology

Biotechs5454 Apr. 14 at 3:30 PM

$AUTL Relative to what we usually see, seems like some bigger bids (and asks) on lvl II than the norm.

2 · Reply

smar312 Apr. 14 at 2:43 PM

2 · Reply

Michael_garic Apr. 14 at 2:01 PM

2 · Reply

Michael_garic Apr. 14 at 1:03 PM

$AUTL Still remember this quote

0 · Reply

NANANANANANANAN Apr. 14 at 12:47 PM

$AUTL Dilution incoming

0 · Reply

Michael_garic Apr. 14 at 12:03 PM

2 · Reply

Michael_garic Apr. 14 at 6:36 AM

$AUTL Wainwright issued more realistic EPS numbers and reiterated buy rating for AUTL https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-outlook-for-autl-earnings-2026-04-13/

1 · Reply

billyl Apr. 14 at 2:49 AM

0 · Reply

gandolf63 Apr. 13 at 11:53 PM

0 · Reply

Michael_garic Apr. 13 at 8:50 PM

$AUTL ALLO interesting day. First the positive announcement, then after hours a 175M stock dilution. This indicates that they need additional funding to continue trials. The joys of biotech.

0 · Reply

Biotechs5454 Apr. 13 at 7:45 PM

$AUTL From last month.

1 · Reply

Michael_garic Apr. 13 at 5:57 PM

$AUTL More info from the ALLO. I think the stock ran up to 4.84 on the MRD data(hype)... then reality set in when they announced the "Long Wait" for EFS(reality). The interim analysis focused on MRD (a surrogate marker). During the conference call, the company noted that the interim Event-Free Survival (EFS) analysis isn't expected until mid-2027, with primary data in mid-2028. That being said they are still up 15%. Oh, the joys of biotech. I'm glad I'm invested in a company that has a revenue generating product... no guessing.

0 · Reply

smar312 Apr. 13 at 5:40 PM

$AUTL https://stocktwits.com/symbol/AUTL#:~:text=and%20Trading%20Ideas-,Autolus%20Therapeutics%20Eyes%20CAR%2DT%20Edge%20With%20AUCATZYL%20Safety%2C%20Expands%20Centers%2C%20Sees%20Margin%20Turnaround,-Autolus%20Therapeutics%20(NASDAQ

0 · Reply

Roadto1mio Apr. 13 at 4:18 PM

$AUTL this stock is still under the radar

1 · Reply

lensplay Apr. 13 at 4:02 PM

$AUTL i'm surprised nobody posted about the shelf offering this morning 150M

2 · Reply

Michael_garic Apr. 13 at 3:30 PM

$AUTL Well the ALLO hype led to a high of 4.84...hype faded quickly down to 3.35 and falling. The rollercoaster world of biotech investing.

2 · Reply

Michael_garic Apr. 13 at 3:04 PM

$AUTL I listened to the webcast this morning with Gil Blum and Christian Itin. These are my takeaways as a layman investor. Expect slow growth this year as physicians get comfortable with obe cel. Expect significant expansion of the available CAR T patients as time goes by due to the safety and outpatient nature of the AUTL product. The investigator trials are showing obe cel can be moved up the treatment chain, would improve the patient burden and life expectancy. NCCN guidelines would have to be changed to make this covered by insurance. This change would bring the patient size closer to 2000+ vs. the current 300 or so. Christian said the Nucleus manufacturing facility could handle these numbers. Christian said expansion into immunotherapy would involve manufacturing expansion. Rather than spend the capital on in-house expansion AUTL is looking at Cellares and other external vendors. Christian said he expects margins to increase throughout 2026. Anyone else listen..have input?

4 · Reply

nopennys Apr. 13 at 2:55 PM

$AUTL Now we go down? Most Probably

2 · Reply

Michael_garic Apr. 13 at 12:19 PM

$AUTL ALLO stock is breaking out today because their trial showed an MRD level (early indicator of whether a patient will relapse was improved by 41%. Their benchmark for success was 25%. 10 of the 12 patients were treated as outpatients. They are trying to prove that you don't need to use the patient's own cells to cure cancer. They use healthy donor cells to create hundreds of batches of treatments thus reducing cost as much as tenfold. They still have a lot of work to do before FDA approval, and they are also going to expand into immunotherapy putting pressure on traditional CAR T.

2 · Reply

Michael_garic Apr. 13 at 12:02 PM

$AUTL Appears ALLO is breaking out based on their positive trial results. Will be interesting to watch what happens today as the stock is heavily shorted and could get squeezed.

0 · Reply

Michael_garic Apr. 13 at 10:15 AM

$AUTL

0 · Reply

yoter Apr. 13 at 9:34 AM

$AUTL Needham reaffirms sp at $9

1 · Reply

Market Cap	396.55M
Revenue (ttm)	75.39M
Net Income (ttm)	-287.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-381.39%
Debt to Equity Ratio	0.00

Volume	750,400
Avg Vol	1,657,822
Day's Range	N/A - N/A
Shares Out	266.14M
Stochastic %K	61%
Beta	2.04
Analysts	Strong Sell
Price Target	$8.77